相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (vol 159, pg 496, 2022)
[Anonymous]
CHEST (2023)
Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review
A. Norden et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
Michael E. Wechsler et al.
LANCET RESPIRATORY MEDICINE (2022)
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
Koichi Ando et al.
CELLS (2022)
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis
Ayobami Akenroye et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Biologics for allergic and immunologic diseases
Hideaki Morita et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis
Michael Benzaquen et al.
BIOENGINEERING-BASEL (2022)
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
C. A. J. Michielsens et al.
DRUGS (2021)
Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
Sady Alpizar et al.
JOURNAL OF ASTHMA AND ALLERGY (2021)
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
Stephanie Korn et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh et al.
CHEST (2021)
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma
Ioana Agache et al.
ALLERGY (2020)
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial
Selma Atalay et al.
JAMA DERMATOLOGY (2020)
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Anna Vaisman-Mentesh et al.
FRONTIERS IN IMMUNOLOGY (2020)
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Kenneth R. Chapman et al.
ALLERGY (2019)
Update on immunogenicity in severe asthma: Experience with mepolizumab
Hector G. Ortega et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
Amit Khatri et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Monoclonal antibodies for severe asthma: Pharmacokinetic profiles
Maria Gabriella Matera et al.
RESPIRATORY MEDICINE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Sumita Khatri et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
Gary T. Ferguson et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
Bao-ping Tian et al.
JOURNAL OF ASTHMA (2018)
Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials
Ting Liu et al.
FRONTIERS OF MEDICINE (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis
Lu-Lu He et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma
Gary T. Ferguson et al.
JOURNAL OF ASTHMA AND ALLERGY (2018)
Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial
Pamela L. Zeitlin et al.
JOURNAL OF ASTHMA AND ALLERGY (2018)
The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis
Jinfeng Li et al.
JOURNAL OF ASTHMA (2017)
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Marta Perez-De-Lis et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study
M. Esposito et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Gary T. Ferguson et al.
LANCET RESPIRATORY MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
G. R. Gunn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma
Richard M. Nowak et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2015)
Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab
Isabelle J. Pouliquen et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma
Laura Somerville et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
Oliver Kornmann et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2014)
Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis One-Year Follow-up
Stef P. Menting et al.
JAMA DERMATOLOGY (2014)
Metaprop: a Stata command to perform meta-analysis of binomial data
Victoria N. Nyaga et al.
ARCHIVES OF PUBLIC HEALTH (2014)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Biologics-induced autoimmune diseases
Roberto Perez-Alvarez et al.
CURRENT OPINION IN RHEUMATOLOGY (2013)
An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment
T. Taniguchi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
Lidian L. A. Lecluse et al.
ARCHIVES OF DERMATOLOGY (2010)
Autoimmune diseases induced by biological agents A double-edged sword?
Manuel Ramos-Casals et al.
AUTOIMMUNITY REVIEWS (2010)
One Year Treatment with Omalizumab Is Effective and Well Tolerated in Japanese Patients with Moderate-to-Severe Persistent Asthma
Ohta Ken et al.
ALLERGOLOGY INTERNATIONAL (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma
W Berger et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2003)
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
R Buhl et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
分享论文
